Rakuten Medical and LOTTE Biologics Sign Manufacturing Agreement to Support Biopharmaceuticals in Global Oncology Program

Rakuten Medical and LOTTE Biologics Sign Manufacturing Agreement to Support Biopharmaceuticals in Global Oncology Program

SAN DIEGO and SEOUL, South Korea, Jan. 13, 2026 /PRNewswire/ -- Rakuten Medical, Inc. and LOTTE Biologics today announced that they have signed a biopharmaceutical contract manufacturing agreement during the J.P. Morgan Healthcare Conference in San Francisco to strengthen Rakuten Medical's production capabilities for its innovative oncology therapy, Alluminox® platform-based photoimmunotherapy. Under the agreement, LOTTE Biologics will provide …

Rakuten and Lotte ink manufacturing deal at J.P. Morgan

The partnership will focus on advancing the production of Rakuten’s oncology platform.

Lotte Biologics, Rakuten Medical sign deal on producing new cancer treatment drug

Lotte Biologics signed a contract manufacturing organization (CMO) agreement with Rakuten Medical on Tuesday to produce and commercialize Rakuten’s photoimmunotherapy (PIT) drug, an antibody-dye conjugate used in the treatment of cancer.